Avacta Group (LON:AVCT) Trading Up 12.4% – Here’s What Happened

Avacta Group Plc (LON:AVCT) shares rose 12.4% during trading on Monday . The stock traded as high as GBX 59 and last traded at GBX 59. Approximately 2,156,725 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 2,379,199 shares. The stock had previously closed at GBX 52.50.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reaffirmed a “buy” rating and set a GBX 99 price target on shares of Avacta Group in a research report on Monday, October 13th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of GBX 99.

Avacta Group Stock Up 12.4%

The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53. The company has a fifty day simple moving average of GBX 72.06 and a 200-day simple moving average of GBX 56.31. The firm has a market cap of £255.86 million, a P/E ratio of -3.36 and a beta of 1.12.

Avacta Group (LON:AVCT) last posted its quarterly earnings data on Tuesday, September 30th. The biotechnology company reported GBX (4.46) earnings per share for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. On average, equities analysts anticipate that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).